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Abstract
Apart from nitric oxide (NO) and carbon monoxide (CO), hydrogen sulfide (H2S) is the 
third gaseous mediator in mammals. H2S is synthesized from L-cysteine by cystathio-
nine β-synthase (CBS), cystathionine γ-lyase (CSe), or by sequential action of alanine 
aminotransferase and 3-mercaptopyruvate sulfurtransferase. in the cardiovascular sys-
tem, H2S is involved in the regulation of vascular tone and blood pressure, inhibits ath-
erogenesis, and protects myocardium from ischemia-reperfusion injury. Recent studies 
indicate that H2S is synthesized also in the adipose tissue. Hydrogen sulfide produced 
in periadventitial adipose tissue (tunica adiposa) of the blood vessels induces vasodila-
tion by activating K+ channels in smooth muscle cells. On the other hand, H2S inhibits 
basal and insulin-stimulated glucose uptake in visceral adipose tissue, and may be in-
volved in the pathogenesis of insulin resistance. H2S production in periadventitla adi-
pose tissue is stimulated by vasoconstrictors and aortic banding-induced hypertension 
and downregulated by aging. H2S signaling in adipose tissue may be affected by phar-
macotherapy. Lipid-soluble statins (3-hydroxy-3-methylglutarylcoenzyme A reductase 
inhibitors) increase H2S level in periadventitial adipose tissue and thus augment its an-
ticontractile effect on the blood vessels. This effect of statins results from the depletion 
of ubiquinone – a component of mitochondrial respiratory chain – and the impairment 
of mitochondrial H2S oxidation.
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Introduction
It was realized during the last two dec-
ades that the family of endogenous 
regulatory mediators includes not only 
complex organic compounds such as 
peptides/proteins, amines (serotonin, 
catecholamines, histamine), purines 
(adenosine, ATP), steroids, etc., but 
also simple inorganic molecules such 
as nitric oxide (NO), carbon monox-
ide (CO) and hydrogen sulfide (H2S); 
now referred to as “gasotransmitters”, 
because in nature they exist in gase-
ous form (1). The first member of 
gasotransmitter family, nitric oxide, 
was identified in 1980s, initially as the 
endothelium-derived relaxing factor. 
Now, it is evident that NO is ubiqui-
tously generated in various tissues by 
three isoforms of NO synthase, and is 
involved in the regulation of vascular 
tone, myocardial contractility, renal 
function, neurotransmission, inflam-
matory response and many other 
processes (2). Soon thereafter, it was 
realized that carbon monoxide (CO), 
synthesized from heme by heme oxy-
genases (HO), is not only a metabolic 
waste product but also an endogenous 
gasotransmitter. CO shares with NO 
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not only the main mechanism of action, i.e. stimulation of solu-
ble guanylyl cyclase, but also many biological activities such as 
vasorelaxation, neurotransmission, anti-inflammatory effect etc. 
(3). H2S is the youngest member of gasotransmitter family. It was 
first suggested in 1996 by prof. Hideo Kimura that endogenously 
generated H2S is a neurotransmitter/neuromodulator (4). This 
hypothesis was later confirmed by many studies and now it is 
evident that H2S is as ubiquitous as NO and CO.
Both NO (5, 6) and CO (7, 8) are synthesized in the adipose 
tissue. H2S research is a rapidly developing field, and, although 
we still know much less about H2S than about its two older 
cousins, several recent studies have demonstrated that H2S is 
also synthesized in the adipose tissue. Thus, we can classify NO, 
CO and H2S as the new family of adipose tissue-derived media-
tors (“adipomediators”) which, we suggest, should be referred 
to as “adipogasotransmitters”. The purpose of this review is to 
describe the current state of knowledge about role of H2S in adi-
pose tissue and its link with obesity/metabolic syndrome.
Chemical properties, synthesis and metabolism of H2S
H2S is the colorless flammable gas with a strong odor of rotten 
eggs, soluble in both water and organic solvents. In aqueous so-
lutions, H2S dissociates into HS
- and H+ ions with a pKa of 6.76. 
At physiological pH of 7.4, about 18.5% of H2S exists as the un-
dissociated form and the rest as the hydrosulfide anion (HS-). 
Undissociated H2S is lipophilic and easily permeates plasma 
membranes (9).
In nature, H2S is formed during anerobic bacterial digestion 
of organic substrates, originates in inorganic reactions in vol-
canic gases, and during chemical or enzymatic transformation 
of sulfur-containing components of food. High amounts of H2S 
are generated in the colon by commensal bacteria by reduction 
of alimentary sulfates. Like NO and CO, H2S is toxic at high 
concentrations and shares with them the main mechanism of 
toxicity – inhibition of cytochrome c oxidase (mitochondrial 
complex IV) (10). In fact, H2S is actually a more potent inhibitor 
of cytochrome c oxidase than cyanide. NO inhibits cytochrome 
c oxidase at physiological concentrations, and through this 
mechanism reduces some detrimental effects of hypoxia by de-
creasing mitochondrial oxygen consumption (11). It is unclear 
if endogenous H2S is generated in amounts sufficient to inhibit 
mitochondrial respiration.
H2S is synthesized by most tissues in our body; the high-
est amounts are generated in the central nervous system, liver 
and kidney. There are three pathways of endogenous H2S for-
mation (12): (i) desulfhydration of L-cysteine by cystathionine 
β-synthase (CBS, EC 4.2.1.22), (ii) desulfhydration of L-cysteine 
by cystathionine γ-lyase (CSE, EC 4.4.1.1), and (iii) transamina-
tion reaction between L-cysteine and α-ketobutyrate catalyzed 
in mitochondria by cysteine aminotransferase (identical with 
aspartate aminotransferase) to form aspartate and 3-mercapto-
pyruvate, followed by decomposition of the latter to pyruvate 
and H2S by 3-mercaptopyruvate sulfurtransferase (3-MST).
CBS and CSE are pyridoxal 5’-phosphate (vitamin B6)-
dependent enzymes, which act sequentially in the transsulfu-
ration pathway to convert L-homocysteine to L-cysteine with 
L-cystathionine as the intermediate (13). Thus, both enzymes are 
necessary for efficient homocysteine metabolism. Desulfhydration 
of L-cysteine to H2S is an additional activity of CBS and CSE 
which, at least under Vmax conditions, is much lower than their 
primary canonical activities in the transsulfuration pathway. 
There are several different mechanisms of H2S synthesis from 
L-cysteine by both CBS and CSE (see ref. (14) for details). Recent 
studies indicate that H2S may be synthesized also directly from 
homocysteine, at least by CSE (14). At physiological concentra-
tions of these aminoacids, about 70% of H2S is synthesized from 
cysteine and the remaining 30% from homocysteine; the contri-
bution of homocysteine increases in hyperhomocysteinemia. The 
third, 3-MST-dependent pathway, was until now observed only in 
vitro in the nervous system (15) and in endothelial cells of some 
species (e.g. rat and human but not mouse) (16), and its contribu-
tion to overall H2S formation is unknown.
Recently, it was demonstrated that CBS and CSE may be re-
leased to the blood by at least two cell types, endothelial cells and 
hepatocytes, and can generate H2S extracellularly from homo-
cysteine circulating in the blood (17). Interestingly, extracellu-
larly formed H2S protects endothelial cells from various insults 
such as serum starvation, hypoxia/reoxygenation or hyperho-
mocysteinemia-induced injury.
The level of endogenous H2S is controversial. In studies in 
which colorimetric methods of H2S assay were applied, values 
between 10 and 50 μM in plasma and even more in some tis-
sues were reported. However, more recent studies suggest that 
most of this H2S is not free but bound as the so-called sulfane 
sulfur, i.e. sulfur atoms bound only to other sulfur atoms, mostly 
in persulfide groups (-SSH) of protein cysteine residues. H2S 
may be released from sulfane sulfur by reducing agents such as 
synthetic thiol-reducing dithiotreitol as well as by endogenous 
glutathione; this reaction is especially efficient at alkaline pH 
(18). Thus, sulfane sulfur may be a reservoir of preformed H2S 
in tissues. Another form of H2S storage is acid labile sulfur, i.e. 
iron-sulfur clusters of proteins, from which H2S is released at 
pH<5.4. Because most of iron-sulfur clusters are contained in 
mitochondrial proteins and intramitochondrial pH is >7.4, acid-
labile sulfur is unlikely to be a physiologically relevant H2S store, 
although may be released during tissue processing before colori-
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occur only at high supraphysiological gas concentrations. In 
contrast to NO and CO, H2S does not stimulate soluble guanylyl 
cyclase. Many biological effects of endogenous H2S have been 
described such as vasorelaxation, inhibition of atherogenesis, 
myocardial protection against ischemia-reperfusion injury, reg-
ulation of inflammatory reaction, neurotransmission and regu-
lation of renal function (28). The link between H2S and adipose 
tissue is just an emerging field of H2S research.
Synthesis of H2S in adipose tissue
Both CBS and CSE are expressed in perirenal; epidydimal and 
perivascular white adipose tissue, as well as in brown adipose 
tissue in the rat (29,30). In addition, the recent study (31) indi-
cates that homocysteine is produced in adipose tissue in high 
amounts. Thus, adipose tissue contains the whole machinery 
required for the transsulfuration pathway of homocysteine me-
tabolism, as well as for the generation of H2S by desulfhydration 
of either cysteine or homocysteine. In 2009 Fang et al (30) first 
demonstrated that incubation of homogenates of rat periaortic 
adipose tissue (PAT) with cysteine in the presence of pyridoxal 
5’-phosphate results in H2S formation. H2S production in PAT 
was similar to aortic wall with removed PAT, and was inhibited 
by 65-75% with CSE inhibitors, propargylglycine or β-cyano-L-
alanine. These CSE inhibitors were slightly more potent (inhi-
bition of H2S production by >80%) in the aortic wall without 
PAT. These data suggest that CSE is the main source of H2S in 
both vascular smooth muscle cells and perivascular adipose 
tissue. In addition, the expression of CSE in PAT was demon-
strated by Western blotting, and CSE protein was found in PAT 
adipocytes by immunohistochemistry (30). H2S concentration 
measured by sensitive sulfur electrode was 2-fold higher in the 
incubation medium of PAT+ than of PAT- rat aortic rings. The 
same group (29) demonstrated H2S production from L-cysteine 
by epidydimal, perirenal and brown adipose tissue. In that study 
(29), both CBS and CSE transcripts were found in these fat pads 
by real-time PCR, however, propargylglycine and β-cyano-L-
alanine inhibited H2S synthesis by >80% confirming that CSE is 
a predominant source of H2S. Both CSE expression and H2S syn-
thesis were also observed in cultured rat epidydimal adipocytes 
and preadipocytes, and H2S production from cysteine was by 
about 30% higher in mature fat cells than in preadipocytes (29). 
These data demonstrate that CSE-H2S pathway exists in fat cells. 
It should be noted that 3-MST dependent pathway of H2S pro-
duction could not be detected in these studies (29, 30), because 
α-ketoglutarate – an obligatory cosubstrate for cysteine ami-
notransferase – was not added. Thus, it cannot be excluded that 
3-MST dependent pathway of H2S production is also operative 
in adipose tissue.
metric H2S assay (12). The level of free H2S measured by more 
specific electrochemical methods is in the low micromolar or 
even nanomolar range (19).
Apart from protein binding, the main reason of low steady-
state H2S concentration in tissues is its rapid metabolism. H2S 
may be oxidized spontaneously by molecular oxygen and/or 
reactive oxygen species. Some of the products such as sulfite 
(SO3
2-) may have their own regulatory role, e.g. as a vasodila-
tor or phagocyte-derived bactericidal agent (20, 21). However, 
most of H2S is oxidized enzymatically in mitochondria. The 
discovery of mitochondrial H2S oxidation is one of the most 
fascinating recent breakthroughs in biology. Since the discov-
ery of role of mitochondria in cell energetic it was widely ac-
cepted that mitochondria can produce ATP only by oxidizing 
organic substrates. In the classic pathway of mitochondrial res-
piration, electrons are transferred from NADH to ubiquinone 
(coenzyme Q) by mitochondrial complex I (NADH:ubiquinone 
oxidoreductase) or from succinate to ubiquinone by complex 
II (succinate:ubiquinone oxidoreductase). Then, reduced coen-
zyme Q (ubiquinol) donates electrons to cytochrome c in the 
reaction catalyzed by complex III (ubiquinol:cytochrome c re-
ductase). Finally, electrons are transferred from cytochrome c 
to molecular oxygen by cytochrome c oxidase (complex IV). 
H2S is the first and the only currently known inorganic sub-
strate for eukaryotic mitochondria which can provide energy 
for ATP synthesis (22). The mechanism of H2S oxidation was 
recently deciphered (23). H2S is first oxidized to elemental sulfur 
by sulfide:quinone oxidoreductase (SQR), which transfers elec-
trons to ubiquinone where they enter the mitochondrial respira-
tory chain. Further steps of H2S oxidation are catalyzed by sul-
fur dioxygenase (elemental sulfur to sulfite) and sulfite oxidase 
(sulfite to sulfate), with sulfate (SO4
2-) being the final product. 
Efficient H2S oxidation is especially vital for colonic epithelial 
cells which are exposed to high amounts of H2S of bacterial ori-
gin. However, in other cells H2S oxidation is also very effective 
and regulates its level. Under hypoxic conditions, H2S oxidation 
is compromised and H2S-mediated signaling is augmented (19); 
it is suggested that H2S operates as an “oxygen sensor” and me-
diates many biological effects of hypoxia such as vasorelaxation 
(24), stimulation of arterial chemoreceptors (25) or regulation of 
sodium transport in the kidney (26). Protein binding and rapid 
oxidation shorten the half-life of H2S making it a locally acting 
auto- and paracrine mediator rather than a circulating hormone.
The most specific signaling mechanism triggered by H2S is 
stimulation of ATP-sensitive potassium channels (KATP). H2S ac-
tivates these channels by converting extracellular cysteine thiol 
groups (-SH) to persulfide groups (-SSH) (27). Some other sign-
aling mechanisms have been suggested, however, most of them 
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Perivascular adipose tissue-derived H2S as a vasodilator
Demonstration of H2S synthesis in periaortic adipose tissue led 
to the question about its function. The natural hypothesis was 
that PAT-derived H2S might be involved in the regulation of vas-
cular tone. H2S produced in vascular smooth muscle and en-
dothelial cells dilates blood vessels by activating ATP-sensitive 
potassium channels (KATP) in smooth muscle cells and inducing 
cell hyperpolarization (28). Intravenously administered H2S or 
its donors decrease blood pressure in experimental animals, and 
deficiency of endogenous H2S has been implicated as a patho-
genic factor in arterial hypertension (28). 
Although neglected in most studies concerning the regula-
tion of vascular tone, perivascular adipose tissue is an integral 
part of the vascular wall and thus should rather be referred to 
as periadventitial adipose tissue or tunica adiposa (32). It was 
first demonstrated in 1991 that rat aortic rings with PAT are less 
responsive to constricting effect of norepinephrine than aortic 
rings without PAT, however, the effect was initially attributed to 
norepinephrine uptake by adipocytes or sympathetic endings 
localized in PAT (33). In 2002, Lohn et al demonstrated that va-
soconstricting effect of angiotensin II, serotonin and phenyle-
phrine (α1-adrenergic agonist) were also smaller in PAT+ than 
in PAT-aortic rings, and suggested that periadventitial adipose 
tissue secretes humoral relaxing factor which they named adi-
pose tissue-derived relaxing factor (ADRF) (34). It was demon-
strated that ADRF activity is not accounted for by nitric oxide, 
cyclooxygenase- or cytochrome P450-dependent arachidonate 
derivatives and adenosine. Furthermore, vasodilating effect of 
ADRF was abolished by high, depolarizing, extracellular K+ con-
centrations, suggesting the involvement of potassium channels. 
In addition, the effect of ADRF was at least partially attenuated 
by KATP channel blocker, glibenclamide. Apart from rat aortic 
rings, subsequent studies demonstrated the anticontractile ef-
fect of periadventitial fat on peripheral arteries, which play more 
significant role in the regulation of systemic vascular resistance 
than conduit vessels such as aorta (35). These data led Fang et al 
to suggest that PAT-derived H2S may function as at least one of 
ADRFs (30). They confirmed that the increase in aortic tension 
induced by serotonin or phenylephrine was lower in PAT+ than 
in PAT-rings, and that in PAT-rings this anticontractile effect 
could be mimicked by exogenous H2S. 
The mixture of L-cysteine and pyridoxal 5’-phosphate (but 
neither of these compounds alone) augmented, whereas CSE in-
hibitors, propargylglycine or β-cyano-L-alanine, abolished the 
anticontractile effect of PAT, while having no effect on vascular 
tone of PAT- rings. Interestingly, contractile responses of PAT+ 
and PAT- rings were not different after pretreatment with prop-
argylglycine. The anticontractile effect of PAT was not affected 
by endothelial removal or NO synthase inhibitor, L-NAME, but 
was abolished by KATP channel blocker, glibenclamide. Moreover, 
transfer of incubation/culture medium from PAT+ aortic rings 
or isolated periadventitial adipocytes to PAT- rings reduced 
constricting effect of phenylephrine, serotonin or angiotensin II, 
and this effect could not be observed if donor PAT was preincu-
bated with CSE inhibitors before medium collection. Taken to-
gether, these results indicate that H2S, produced in PAT by CSE, 
reduces vasoconstriction by activating KATP channels in smooth 
muscle cells.
Subsequently, Schleifenbaum et al (36) have demonstrated 
that the presence of PAT also impairs serotonin-induced con-
tractility of rat mesenteric artery. In contrast to aortic rings, the 
anticontractile effect of PAT on the mesenteric artery was not 
affected by KATP channel antagonist, glibenclamide, but was re-
duced by nonspecific inhibitor of voltage-sensitive K+ channels 
(Kv), 4-aminopyridine, as well as by the specific antagonist of 
Kv7.x (KCNQ) channels, XE991. In contrast, XE991 had no ef-
fect on serotonin-induced contraction of mesenteric artery rings 
with removed PAT. Similarly to aorta, anticontractile effect of 
PAT on the mesenteric artery was abolished by CSE inhibitors. 
In addition, NaHS relaxed mesenteric artery rings without PAT, 
and this effect was inhibited by XE991. Taken together, these 
data indicate that PAT-derived H2S reduces vascular tone also in 
small resistance arteries, however, in contrast to aorta its effect 
on smooth muscle cells is not mediated by KATP but rather by 
KCNQ channels. In addition, those authors (36) demonstrated 
that the other gasotransmitter, carbon monoxide, does not me-
diate PAT-induced inhibition of vasoconstriction because this 
effect was not reduced by heme oxygenase inhibitors. It was also 
demonstrated that KCNQ channel activators such as retigabine 
or VRX0621688 induced more prominent vasorelaxation of 
PAT- rings or PAT+ rings treated with CSE inhibitor in compari-
son to PAT+ rings not treated with CSE inhibitors. These results 
indicate that KCNQ channel-mediated vasorelaxing mechanism 
is “saturated” by PAT-derived H2S under physiological condi-
tions. Thus, KCMQ channel activators might be especially useful 
vasodilators when CSE-H2S pathway in PAT is impaired.
Regulation of H2S in periadventitial adipose tissue by 
hemodynamic factors
Given the role of PAT-derived H2S in the regulation of vascular 
tone, it is interesting if and how the CSE-H2S pathway in PAT 
is modulated by hemodynamic factors. Fang et al (30) have 
demonstrated that phenylephrine, serotonin and angiotensin II 
increased H2S production from L-cysteine in isolated PAT. In 
contrast, these vasoconstrictors reduced H2S production in aor-
tic rings without PAT. Because stimulation of H2S release was 
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observed in isolated PAT without adjacent aortic wall, it could 
not result from vasoconstriction itself but rather from the direct 
effect of these mediators on adipose cells.
In experimental hypertension induced in the rat by constric-
tion of the abdominal aorta, H2S synthesis and CSE expression 
in the aortic wall without PAT was unchanged in comparison 
to control normotensive animals, however, H2S production and 
CSE expression in PAT increased by 70% and 130%, respec-
tively. Plasma H2S level was also slightly higher in hyperten-
sive animals. Thus, CSE-H2S system in PAT could be a back-up 
vasodilatory mechanism, which is up-regulated in response to 
both acute effect of vasoconstrictors and chronic hypertension. 
The mechanism of CSE-H2S up-regulation in PAT in hyperten-
sive rats is unclear, but the effect could partially results from 
higher concentration of angiotensin II in this model.
Interestingly, transplantation of PAT from healthy donor rats 
to the stenotic area of the abdominal aorta of hypertensive rats 
decreased systolic and diastolic blood pressure in hypertensive 
animals, but this effect could not be reproduced by transplanta-
tion of subcutaneous adipose tissue (30). Consequently, trans-
plantation of PAT (but not of subcutaneous adipose tissue) re-
duced myocardial hypertrophy as well as decreased angiotensin 
II concentration in plasma and aortic wall of hypertensive ani-
mals. Although it was not examined if these effects were medi-
ated by PAT-derived H2S, this possibility is likely since H2S was 
recently demonstrated to suppress renin-angiotensin system by 
inhibiting renin secretion (37) and angiotensin-converting en-
zyme activity (38).
Aging is well-known to exert detrimental effects on endothe-
lium-dependent vasorelaxation. The effect of age on CSE-H2S 
system in periadventitial adipose tissue was also examined 
(30). In the rat, H2S production in PAT decreased between 6 
and 12 months by 35%-64% in comparison to 1-month old ani-
mals. Surprisingly, CSE expression markedly increased in PAT 
in age-dependent manner starting from 2 months. It could be 
hypothesized that up-regulation of CSE is a negative feedback 
response to H2S deficiency. However, CSE expression was mark-
edly higher already in 2-month old in comparison to 1-month 
old rats, whereas H2S production in 2-month old rats was still 
normal (30). The alternative explanation is that during ageing 
CSE becomes “dysfunctional”, i.e. H2S production is reduced de-
spite greater amount of enzymatic protein. The similar, although 
less pronounced, age-dependent decrease in H2S production de-
spite concomitant up-regulation of CSE was also observed in rat 
aortic rings without PAT (30). Interestingly, although CSE ex-
pression increased between 2 and 12 months of age also in epi-
dydimal and perirenal fat pads, this was accompanied by parallel 
increase in H2S production (29). Thus, although CSE expression 
during aging behaves similarly in PAT and in other parts of vis-
ceral fat tissue, H2S production changes in opposite directions. 
The reason for this difference between PAT and epidydimal/
perirenal fat is unclear.
H2S in adipose tissue as the regulator of insulin sensitivity
In freshly isolated rat epidydimal adipocytes, H2S in solution 
(10-1000 μM) reduced basal and insulin-stimulated uptake of 
glucose as well as of non-metabolizable 2-deoxyglucose in a 
time and concentration-dependent manner (29). Although H2S 
concentration used in this study was relatively high, the effect 
seems to be physiologically relevant because was reproduced 
when adipocytes were incubated in the presence of cysteine 
and pyridoxal 5’-phosphate to increase endogenous H2S forma-
tion. Moreover, either propargylglycine or β-cyano-L-alanine 
not only abolished cysteine+pyridoxal phosphate-induced re-
duction of basal or insulin-stimulated glucose uptake, but also 
reduced baseline H2S production in adipocytes and stimulated 
glucose uptake either in the absence or in the presence of in-
sulin. These data indicate that H2S produced under physiologi-
cal conditions regulates glucose uptake and insulin sensitivity 
of adipocytes. Interestingly, the effect of H2S on glucose uptake 
was not inhibited by KATP channel antagonist, glibenclamide, but 
was abolished by phosphoinositide 3-kinase (PI3-K) inhibitor, 
LY294002 (29). Although H2S has been demonstrated to stimu-
late PI3-K in other tissues, this result is surprising since PI3-K 
is also a main insulin-triggered signaling mechanism. The ex-
act intracellular mechanism through which H2S impairs glu-
cose uptake in adipocytes is not clear, however, it was recently 
noted that H2S inhibits cyclic AMP and cyclic GMP-degrading 
phosphodiesterases (39). Since both these cyclic nucleotides 
stimulate lipolysis in adipocytes (40) and enhanced lipolysis is 
associated with reduced glucose uptake, this mechanism may 
contribute to H2S-induced insulin resistance.
In primary culture of epidydimal rat adipocytes, high con-
centrations of glucose reduced H2S production in a time- and 
concentration-dependent manner (29). The effect of glucose was 
not reproduced by mannitol thus indicating that it does not re-
sult from hyperosmolality but rather is specific for glucose. Thus, 
the negative feedback regulatory mechanism between glucose 
and H2S may exist in adipose tissue, with H2S inhibiting glucose 
uptake and glucose inhibiting CSE-H2S pathway. Furthermore, 
CSE expression and H2S production in adipose tissue was up-
regulated in rats fed high fructose diet for 12 weeks, which is a 
widely used experimental model of insulin resistance (29). In 
addition, the significant negative correlation between H2S pro-
duction and insulin-stimulated glucose uptake in the adipose 
tissue was observed. This observation suggests that CSE-H2S 
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system in adipose tissue may contribute to insulin resistance in 
the metabolic syndrome (29).
Effect of obesity/metabolic syndrome on H2S signaling system
As noted above, high-fructose feeding is associated with the 
up-regulation of CSE-H2S system in the epidydimal and peri-
renal adipose tissue. High fructose diet results in hypertriglyc-
eridemia, insulin resistance, hyperinsulinemia and, according 
to some studies, arterial hypertension (41). Later, progressive 
deterioration of carbohydrate metabolism is observed such 
as impaired glucose tolerance or even fasting hyperglycemia. 
Consistently with results observed in visceral adipose tissue, it 
was found higher expression and activity of CBS and CSE in the 
liver in Zucker diabetic fatty (ZDF) rats at the 5th week of age 
when these animals are insulin resistant and hyperinsulinemic 
but still nonrmoglycemic (42).
However, the effect of metabolic syndrome on CSE and CBS 
expression/activity is controversial. Experimental obesity in-
duced in the rat by high fat and high sucrose feeding resulted in 
the reduction of CBS expression and activity in the liver, which 
was accompanied by about 50% elevation of plasma homo-
cysteine (43). Most experimental data indicate that insulin down-
regulates the expression of CBS and CSE in the liver (44,45), and 
insulin deficiency in streptozotocin-induced diabetes is associ-
ated with the elevation of these enzymes, reduction of plasma 
homocysteine, and overproduction of H2S (46,47). Thus, hyper-
insulinemia could result in the down-regulation of H2S produc-
tion if insulin sensitivity is preserved. Recently, Whiteman et al 
(48) compared plasma H2S levels in 11 lean, 16 overweight non-
diabetic and 11 overweight type 2 diabetic males. Plasma H2S 
was lower in normoglycemic overweight than in lean volunteers, 
and was negatively correlated with markers of insulin sensitiv-
ity such as HOMA-index or insulin tolerance test. However, the 
strongest negative correlations were observed between H2S and 
measures of central adiposity such as waist circumference and 
waist-to-hip ratio (r=-0.65). Multiple regression analysis dem-
onstrated that high waist circumference was an independent 
predictor of low plasma H2S level even after adjusting for insulin 
resistance. In overweight diabetic patients plasma H2S was even 
lower than in overweight non-diabetic subjects (48). Although 
plasma H2S originates from various sources apart from adipose 
tissue, these results would be consistent with the downregula-
tion of H2S producing enzymes in obesity.
Adipopharmacology of H2S 
PAT-derived H2S may be involved not only in the regulation of 
vascular tone but may also inhibit atherogenesis. Indeed, H2S 
exerts many potentially antiatherogenic effects such as inhibi-
tion of vascular smooth muscle cell proliferation, antiplatelet 
activity, inhibition of LDL oxidation and antiinflammatory ef-
fect (28). Recently, it has been demonstrated that H2S inhibits 
atherogenesis in apolipoprotein E knockout mice (49). Thus, 
enhancing H2S production by PAT and/or other parts of the 
vascular wall could be a useful therapeutic approach in cardio-
vascular disorders. Unfortunately, currently available inorganic 
H2S donors such as NaHS, Na2S or Ca2S, although widely used 
in experimental studies, are unsuitable for therapy because are 
unstable (undergo spontaneous oxidation in solutions in vitro) 
and release H2S rapidly and in high amounts in vivo (50). Some 
new organic H2S donors such as GYY4137 have been synthe-
sized which release H2S slowly and in moderate amounts. They 
exert a more persistent effect on vascular tone and blood pres-
sure (51). However, these compounds are still in the early stage 
of preclinical development, and their potential use in therapy 
is a matter of future. Thus, the effect of drugs currently used in 
cardiovascular disorders on H2S signaling is highly interesting.
Recently, we examined the effect of statins on H2S production 
in the vascular wall. Statins are competitive inhibitors of 3-hy-
droxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, a 
rate-limiting enzyme in cholesterol synthesis, which converts 
HMG-CoA to mevalonate. Statins reduce plasma LDL choles-
terol and are very effective in primary and secondary prevention 
of ischemic heart disease (52). Apart from affecting cholesterol 
metabolism, statins inhibit synthesis of many other active prod-
ucts of the mevalonate cascade including: (i) farnesylpyrophos-
phate – a substrate for protein farnesyltransferase which attaches 
farnesyl group to small GTP-binding Ras proteins; farnesylpyro-
phosphate is also necessary for the synthesis of heme A which is 
a specific component of cytochrome c oxidase, (ii) geranylgera-
nylpyrophosphate – a substrate for protein geranylgeranyltrans-
ferase which prenylates small GTP-binding Rho proteins, (iii) 
dolichol, involved in protein glycosylation, (iv) coenzyme Q 
(CoQ, ubiquinone) – a component of mitochondrial respiratory 
chain, (v) intermediates in cholesterol synthesis and hydroxy-
lated cholesterol derivatives (oxysterols), which are endogenous 
agonists of the nuclear receptor – liver X receptor (LXR), and 
(vi) isopentenyladenosine required for selenoprotein synthesis. 
Reduction of these mevalonate metabolites is responsible for the 
so-called pleiotropic effects of statins, independent from the de-
crease in blood cholesterol. Statins can be classified according to 
their solubility into hydrophilic (pravastatin, rosuvastatin) and 
lipophilic (fluvastatin, simvastatin, atorvastatin, pitavastatin). 
Hydrophilic statins poorly permeate plasma membranes and are 
considered more liver-specific because are effectively transport-
ed to hepatocytes by organic anion transporters. Consequently, 
although hydrophilic statins affect the lipid profile, they posses 
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less peripheral effects. In contrast, lipophilic statins permeate ef-
fectively both to hepatocytes and to peripheral tissues. Previous 
studies have demonstrated that (especially lipophilic) statins 
have many effects on adipose tissue function (reviewed in 52).
We used two representant statins: hydrophilic pravastatin 
and lipophilic atorvastatin, and administered them for 3 weeks 
to healthy normolipidemic rats at doses which exerted compa-
rable effects on plasma lipids (53). Then, we examined H2S for-
mation catalyzed by tissue (aortic media and PAT) homogenates 
under optimal conditions (saturating L-cysteine and pyridoxal 
5’-phosphate concentrations). We found that only atorvastatin, 
but not pravastatin, increased H2S production in PAT, whereas 
neither statin had any effect in the aortic media. Both statins 
increased H2S production in the liver. Thus, we identified new 
pleiotropic, lipid-independent, effect of statins in the vascular 
wall which may contribute to beneficial impact of these drugs on 
atherogenesis and vascular tone.
In our initial experiments we used post-nuclear tissue ho-
mogenates which contain both cytosol (where CSE is localized) 
and mitochondria. Thus, it is unclear if the increase in net H2S 
production resulted from increased synthesis or reduced mi-
tochondrial oxidation. To address this issue, we measured H2S 
production separately also in post-mitochondrial supernatants. 
We found that H2S formation in post-mitochondrial superna-
tants of both PAT and liver was higher than in post-nuclear su-
pernatant. That the difference in H2S production between post-
mitochondrial and post-nuclear supernatants indeed represents 
mitochondrial H2S oxidation was confirmed by two observa-
tions: (i) this difference was abolished to virtually zero if the 
measurement was performed in carefully deoxygenated buffer 
to stop mitochondrial H2S oxidation, and (ii) the difference was 
markedly inhibited by myxothiazole (mitochondrial complex 
III inhibitor) and potassium cyanide (cytochrome c oxidase in-
hibitor) but not by rotenone – inhibitor of complex I which is 
not involved in H2S oxidation. Atorvastatin increased net H2S 
production only in post-nuclear but not in post-mitochondrial 
supernatant and thus reduced the estimated mitochondrial H2S 
oxidation in PAT. Similarly, both statins had the same effect in 
the liver. In support of these results, we found that oxidation of 
NaHS in vitro by isolated liver mitochondria was reduced in 
statin-treated in comparison to control rats. We could not ob-
tain sufficient amount of isolated mitochondria from PAT to 
measure NaHS oxidation in vitro, however, taken together these 
results indicate that statins reduce mitochondrial H2S oxidation 
but have no effect on cytosolic H2S synthesis. Consistently with 
this conclusion, statins had no effect on CSE activity toward cys-
tathionine in either PAT or the liver.
Next, we asked which products of the mevalonate cascade are 
responsible for the effect of statins on H2S. To answer this ques-
tion, we supplemented statin-treated rats with various meval-
onate products or the mevalonate itself at doses which, accord-
ing to previous studies, restored their levels to control values 
(54). We found that only mevalonate itself, farnesol and coen-
zyme Q9 (the major coenzyme Q species in the rat) normalized 
mitochondrial H2S oxidation in the liver in atorvastatin or prav-
astatin-treated rats and in PAT in atorvastatin-treated rats. These 
data suggest that statins inhibit H2S oxidation by suppressing 
coenzyme Q synthesis, because mevalonate and farnesol, as well 
as exogenous coenzyme Q9, correct reduced CoQ concentration 
in statin-treated rats. In contrast, squalene and geranylgeraniol, 
which are not CoQ precursors, failed to normalize H2S produc-
tion (53, 54). Similarly, synthetic LXR agonist, TO901317, also 
did not restore mitochondrial H2S oxidation in statin-treated 
rats. In addition, incubation of liver mitochondria isolated from 
atorvastatin-treated rats with exogenous CoQ9 in vitro normal-
ized NaHS oxidation. Supplementation of CoQ9 either in vivo 
or in vitro in rats not treated with statins had no effect on H2S 
oxidation, although increased tissue and plasma CoQ9 above 
control levels. These data indicate that physiological CoQ con-
centration (until compromised by statin treatment) is sufficient 
to support optimal H2S oxidation.
Consistently with these results, no effect on H2S oxidation 
was observed in animals receiving more specific inhibitors of the 
mevalonate cascade acting distally from mevalonate and having 
no effect on CoQ such as zaragozic acid (squalene synthase in-
hibitor), perillic acid (protein farnesyl- and geranylgeranyltrans-
ferase inhibitor), fasudil (which inhibits Rho-activated protein 
kinase) or farnesylthiosalicylic acid, an inhibitor of farnesylated 
Ras proteins. Neither of these inhibitors, in contrast to atorvas-
tatin, affected coenzyme Q synthesis and H2S level in the liver 
and periaortic adipose tissue.
Statins have been demonstrated to reduce CoQ in plasma 
and tissues of both experimental animals and humans (55), and 
statin-induced CoQ deficiency is implicated in the pathogenesis 
of some adverse effects of these drugs such as hepato- and myo-
toxicity. The results obtained by us indicate that CoQ depletion 
may also contribute to some desirable effects of statins.
Obviously, coenzyme Q is involved not only in H2S oxida-
tion but also in electron transfer from organic substrates to mo-
lecular oxygen. Thus, the question appears if statins specifically 
reduce mitochondrial oxidation of H2S or affect also oxidation 
of organic substrates? In the latter case, statins would compro-
mise ATP production and induce cell energy deficit. Data about 
the effect of statins on mitochondrial respiration are scarce and 
mainly obtained using models of statin-induced myopathy and/
or hepatotoxicity. No previous studies addressed the effect of 
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statins on mitochondrial function in adipose tissue. Because we 
could not obtain sufficient amount of mitochondria from PAT, 
we isolated mitochondria from the liver of statin-treated rats and 
measured oxidation of NaHS as well as of organic substrate of 
complex II, succinate. We measured two markers of mitochon-
drial function: ATP production and mitochondrial membrane 
potential (Δψm). Δψm is potential difference across inner mito-
chondrial membrane, between mitochondrial matrix and mito-
chondrial intermembrane space (negative potential in matrix). 
During electron transport through the mitochondrial respira-
tory chain, protons (H+) are also transferred from matrix to in-
termembrane space. The resulting H+ gradient provides energy 
for ATP synthesis and makes mitochondria the most negatively 
charged organelles in the cell with Δψm from -150 to -180 mV. 
Thus, Δψm is a global marker of electron transport efficacy. We 
measured Δψm in suspended liver mitochondria by lipophilic 
cationic fluorescent probe, JC-1 (54). This probe accumulates in 
negatively charged space of mitochondrial matrix and changes 
not only the intensity but also the character of fluorescence in 
a concentration-dependent manner. In diluted solutions, JC-1 
exists as monomers which, when excited with the wavelength 
of 488 nm, emit green light at 535 nm. When JC-1 concentra-
tion increases, aggregates are formed which exhibit maximal 
emission within the orange range (595 nm). The ratio between 
intensity of orange-to-green fluorescence increases very sharply 
with increasing JC-1 concentration which, inside mitochondria, 
is proportional to Δψm (56). To measure Δψm, we incubated 
suspended liver mitochondria with 1 μM JC-1 in the presence 
of either succinate or NaHS, and then measured fluorescence 
at both wavelengths to calculate this ratio. We found that Δψm 
measured in the presence of succinate was similar in control and 
statin-treated rats. In contrast, Δψm measured in the presence of 
NaHS was significantly lower in statin-treated in comparison to 
control group (54). In addition, the highly significant correlation 
between Δψm in the individual samples and NaHS oxidation (the 
rate of decrease in NaHS concentration) was observed. Similar 
results were obtained when ATP synthesis by isolated mitochon-
dria was assessed. These results indicate that statins specifically 
reduce H2S oxidation while having no effect on oxidation of 
organic substrates. We suggest that this specificity is accounted 
for by different Km values of SQR vs. complex I/complex II for 
coenzyme Q, however, this hypothesis requires further research. 
Because under physiological conditions H2S constitutes only a 
minor fraction of mitochondrial substrates, this effect of statins 
is unlikely to impair ATP production and cell energy status but 
is related only to H2S signaling.
Conclusions and future directions
The most important messages resulting from studies performed 
so far are as follows: (i) H2S is synthesized in adipose tissue, 
mainly by CSE, (ii) H2S produced by periadventitial adipose tis-
sue is a vasodilator; it induces hyperpolarization of adjacent vas-
cular smooth muscle cells in large conduit and small resistance 
arteries by activating KATP and KCNQ channels, respectively, (iii) 
in visceral adipose tissue, H2S inhibits basal and insulin-stimu-
lated glucose uptake and thus may be involved in insulin resist-
ance, (iv) CSE-H2S system in the adipose tissue is regulated by 
physiological (e.g. vasoconstrictors, aging), pathological (hyper-
glycemia, hypertension, fructose-induced metabolic syndrome) 
and pharmacologic (statins) factors, and (v) apart from CSE ex-
pression and activity, H2S level in the adipose tissue is depend-
ent on its mitochondrial oxidation and thus may be affected by 
factors such as coenzyme Q availability.
Several important issues for future research emerge from data 
presented above. First, our study with statins was performed 
only on periadventitial adipose tissue surrounding the aorta. 
This tissue contains many brown adipocytes which are very rich 
in mitochondria. We estimated that about 50% of synthesized 
H2S in this tissue is immediately oxidized. Other parts of visceral 
and subcutaneous adipose tissue (with the exception of brown 
adipose tissue itself) contain much less or no brown adipocytes 
and thus the relative contribution of mitochondrial oxidation 
to H2S signaling is unclear. If mitochondrial oxidation plays an 
important role in the regulation of H2S level not only in periad-
ventitial but also in other fat pads, H2S might be up-regulated by 
adipose tissue hypoxia which is observed in obesity (57). In view 
of possible role of H2S in inducing insulin resistance (29) and a 
well-documented role of adipose tissue hypoxia in insulin resist-
ance (57), this possibility becomes highly interesting.
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